



MINISTERIO  
DE SANIDAD, SERVICIOS SOCIALES  
E IGUALDAD

**am** agencia española de  
medicamentos y  
productos sanitarios

DEPARTAMENTO DE  
MEDICAMENTOS  
VETERINARIOS

# Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8  
28022 – Madrid  
España  
(Reference Member State)

DECENTRALISED PROCEDURE

## PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

**OVUCRON 0.025 mg/ml solution for injection for cattle and  
rabbits.**

CORREO ELECTRÓNICO

[mresvet@aemps.es](mailto:mresvet@aemps.es)

HH\_PAR\_EN\_001\_002.doc

F-DMV-25-02

C/ CAMPEZO, 1 – EDIFICIO 8  
28022 MADRID  
TEL: 91 822 54 01  
FAX: 91 822 5443

## MODULE 1

### PRODUCT SUMMARY

EU Procedure number	ES/V/0269/001/DC
Name, strength and pharmaceutical form	OVUCRON 0.025 mg/ml solution for injection for cattle and rabbits.
Applicant	FATRO S.p.A. - Via Emilia, 285 - Ozzano Emilia (Bologna), Italy
Active substance(s)	Lecirelin
ATC Vet code	QH01CA92
Target species	Cattle (cows) and female rabbits for reproduction.
Indication for use	Cattle (cows) Treatment of follicular ovarian cysts. Induction of ovulation at the time of insemination in cases of short, silent heat or prolonged heat. Rabbits Induction of ovulation. Conception rate enhancement.



## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (<http://www.hma.eu>).

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	24/10/2016 D210: 21/12/2016
Date product first authorised in the Reference Member State (MRP only)	-
Concerned Member States for original procedure	SK, CZ

#### I. SCIENTIFIC OVERVIEW

##### ***For public assessment reports for the first authorisation in a range:***

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

## II. QUALITY ASPECTS

### A. *Composition*

The product contains 0.025 mg/ml of lecorelin (as acetate) and benzyl alcohol, glacial acetic acid, disodium phosphate dodecahydrate, Sodium chloride and water for injections as excipients.

The container/closure system is a colourless type I glass vial (2 and 10 ml) or colourless type II glass vial (20 ml), closed with a chlorobutyl rubber stopper type I and sealed with a flip-off aluminium collar, in a cardboard box. The particulars of the containers and controls performed are provided and conform to the regulation.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### B. *Method of Preparation of the Product*

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### C. *Control of Starting Materials*

The active substance is lecorelin (as acetate), an active substance which is not described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

### E. *Control on intermediate products*

The tests performed during production are described.

### F. *Control Tests on the Finished Product*

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.



Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

**G. Stability**

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

**H. Genetically Modified Organisms**

Not applicable

**J. Other Information**

### **III. SAFETY AND RESIDUES ASSESSMENT**

As this is a generic application according to Article 13.1 of the Directive 2001/82/EC as amended, and bioequivalence with a reference product has been demonstrated, results of safety and residue tests are not required.

The safety and residue aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are similar to those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers.

#### **III.A Safety Testing**

##### ***Pharmacological Studies***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, the results of pharmacological studies are not required.

##### ***Toxicological Studies***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, the results of toxicological studies are not required.

##### ***User Safety***

The applicant has not provided a user risk assessment. OVUCRON 0.025 mg/ml solution for injection for cattle and rabbits will be used in the same species, at the same doses and treatment regimen, and has the same qualitative and quantitative composition as the reference product. For these reasons, the risk for the user can be considered identical for both products.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

##### ***Ecotoxicity***

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required. The assessment concluded that this veterinary medicinal product is a hormone used as reproductive aid for individual animals, it is extensively metabolized in the treated animals and the concentrations found in the environment after its use (PECsoil) are largely below the trigger value of 100 µg/kg.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.



### **III.B Residues documentation**

#### **Residue Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, no residue depletion studies are required.

#### **MRLs**

Lecirelin is included in Table 1 of the Commission Regulation (EC) No. 37/2010 with a No-MRL required status in cattle and rabbits.

#### **Withdrawal Periods**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, the same withdrawal periods are justified:

- Meat and offal: zero days
- Milk: zero days





#### **IV. CLINICAL ASSESSMENT (EFFICACY)**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.



## V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

## MODULE 4

### POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website ([www.hma.eu](http://www.hma.eu)).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>

**or**

*Complete this section for extensions to the same VPA range or defined, significant variations, using the table shown below.*

*Some examples of significant changes in safety or efficacy data are:*

- *Changes to pharmacokinetic data leading to a change in the SPC*
- *Changes to toxicological data leading to a change in the SPC*
- *Changes to user safety warnings*
- *Changes to ecotoxicological information as given in the SPC or changes to disposal warnings*
- *New residue studies in new target species or tissues*
- *Reassessment of residue data or new studies resulting from changes to MRL*
- *Changes to withdrawal period*
- *Changes to target species*
- *Changes to target species tolerance data leading to change in warnings/precautions for target species*
- *New or changed indications*

*Significant changes in administrative or quality data include any Type II change, which affects the initial report. The following Type IA or IB changes may also apply:*

- *Name of product [Type IA: 2]*
- *Name of active substance [Type IA: 3]*
- *MAH [Type IA: 1]*
- *Composition of the medicinal product [Type IB: 18, Type IA/B: 25, 34, 35, 39]*
- *Container/closure system [Type 1/B: 26, 28, 29, 36, 41, 43]*
- *Method of preparation [Type 1B: 33]*
- *Active substance specification [Type IB: 25]*
- *CEP [Type IA/B: 15]*
- *Re-test period or storage conditions of active substance [Type IB: 17]*
- *Excipient specifications [Type 1A/B: 25]*
- *Packaging materials [Type 1A/B: 28, 29, 36, 41, 43]*
- *TSE [Type 1A: 16, 22]*
- *Shelf-life or storage conditions of the finished product [Type 1B: 42]*

### Quality changes

Summary of change (Application number)	Section updated in Module 3	Approval date
<Example: Change to active substance specification> (MS/V/XXX/X/IB/XX)	N/A	

### Safety/efficacy changes

Summary of change (Type; application number)	Section updated in Module 3	Approval date
<Example: Addition of target species - pigs> (MS/V/XXX/X/II/XX)	<III A> <III B> <IV>	